Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Diabetes Care

• Publication date

  2016-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc16-1340PMID 27926897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

  2015cited by this paper
• Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

  2015cited by this paper
• Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice

  2006cited by this paper

• Increased hepatic gluconeogenesis and type 2 diabetes mellitus.

  2024cites this paper
• The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures

  2024cites this paper
• Transforming obesity: The advancement of multi-receptor drugs.

  2024cites this paper
• The glucagon-receptor antagonist MK-3577 reduces glucagon-stimulated plasma glucose and insulin concentrations in metabolically healthy overweight cats.

  2024cites this paper
• Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes

  2024cites this paper
• ErbB3 is required for hyperaminoacidemia-induced pancreatic α cell hyperplasia

  2024cites this paper
• The relationship between glucose and the liver-alpha cell axis – A systematic review

  2023cites this paper
• A bright future for glucagon and alpha cell biology.

  2023cites this paper
• The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

  2023cites this paper
• Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells

  2023cites this paper
• The molecular pharmacology of glucagon agonists in diabetes and obesity

  2023cites this paper
• High glucose-induced glucagon resistance and membrane distribution of GCGR revealed by super-resolution imaging

  2023cites this paper
• Should metformin remain the first-line therapy for treatment of type 2 diabetes?

  2021cites this paper
• Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics

  2020cites this paper
• Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism

  2020cites this paper
• Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

  2019cites this paper
• The metabolic role of vagal afferent innervation

  2018cites this paper
• The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities

  2017cites this paper
• Self-Stabilizing Ampholytic Starch Excipients for Sustained Release of Highly Soluble Drugs: the Case Study of Metformin

  2017cites this paper
• Metformin: New Preparations and Nonglycemic Benefits

  2017cites this paper
• The mechanisms of action of metformin

  2017cites this paper
• Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

  2017cites this paper
• Metformin and Chronic Renal Disease: Proposal for a “Territorial” Therapeutic Diagnostic Path

  2017cites this paper
• Managing Diabetic Nephropathies in Clinical Practice: Emerging and Future Therapies

  2017cites this paper
• Metformin: clinical topics and new mechanisms of action

  2017cites this paper
• The effects of metformin on gut microbiota and the immune system as research frontiers

  2017cites this paper
• Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

  2016cites this paper
• Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus

  2016cites this paper
• Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

  2016cites this paper
• Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials

  2016cites this paper
• Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview

  2016cites this paper